Single Ascending Dose Study of MSD-001 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

June 19, 2025

Study Completion Date

July 11, 2025

Conditions

Mental Health Disorders

Interventions

DRUG

MSD-001

MSD-001 is being developed as part of future two-agent combination treatment approaches for the management of mental health indications

DRUG

Placebo Comparator

Matching Placebo

Trial Locations (1)

Centre for Human Drug Research, Leiden